1. Home
  2. GH vs TMDX Comparison

GH vs TMDX Comparison

Compare GH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$101.88

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$136.41

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
TMDX
Founded
2011
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1B
3.9B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
GH
TMDX
Price
$101.88
$136.41
Analyst Decision
Strong Buy
Buy
Analyst Count
21
10
Target Price
$79.19
$133.00
AVG Volume (30 Days)
2.4M
835.5K
Earning Date
10-29-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
170.70
EPS
N/A
2.54
Revenue
$902,569,000.00
$566,354,000.00
Revenue This Year
$34.72
$38.84
Revenue Next Year
$26.46
$20.43
P/E Ratio
N/A
$53.83
Revenue Growth
30.38
41.20
52 Week Low
$29.91
$55.00
52 Week High
$112.43
$156.00

Technical Indicators

Market Signals
Indicator
GH
TMDX
Relative Strength Index (RSI) 56.90 54.31
Support Level $103.36 $133.50
Resistance Level $109.59 $156.00
Average True Range (ATR) 5.54 8.50
MACD -1.11 0.41
Stochastic Oscillator 42.83 55.98

Price Performance

Historical Comparison
GH
TMDX

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: